Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this drug developer would post earnings of $0.10 per share when it actually produced earnings of $0.11, delivering a surprise of 10%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Compugen , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.56 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 8.28%. This compares to zero revenues a year ago. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Compugen shares have added about 6.6% since the beginning of the year versus the S&P 500's gain of 11.2%. What's Next fo
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan [Yahoo! Finance]Yahoo! Finance
- MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update [Yahoo! Finance]Yahoo! Finance
ROIV
Earnings
- 5/30/24 - Beat
ROIV
Sec Filings
- 6/24/24 - Form 4
- 6/24/24 - Form 4
- 6/24/24 - Form 4
- ROIV's page on the SEC website